ebov
sera
collect
studi
end
point
antivir
therapeut
zebovmakona
sebovgulu
studi
test
crossreact
igg
antibodi
sebov
zebov
enzymelink
immunosorb
assay
elisa
use
recombin
zebov
gp
integr
biotherapi
recombin
sebov
gp
sino
biolog
purifi
viruslik
particl
vlp
contain
nucleoprotein
np
viral
protein
gp
antigen
appropri
ebov
use
detect
crossreact
igg
previous
describ
vlp
produc
previous
describ
avid
measur
total
igg
ebov
gp
determin
use
displac
elisa
establish
concentr
sodium
thiocyan
nascn
need
dissoci
antibodyantigen
interact
briefli
immulon
maxisorp
flatbottom
plate
catalog
thermo
fisher
coat
hour
either
recombin
zebov
gp
integr
biotherapi
recombin
sebov
gp
sino
biolog
sebov
vlp
zebov
vlp
carbonatebicarbon
buffer
plate
wash
twice
phosphatebuff
salin
pb
block
hour
room
temperatur
microliterswel
contain
fetal
bovin
serum
fb
plate
wash
time
microliterswel
contain
nhp
serum
sampl
assay
duplic
use
previous
determin
dilut
zebovc
sebovc
produc
od
nm
plate
incub
hour
room
temperatur
wash
increas
concentr
sodium
thiocyan
dilut
pb
use
treat
well
minut
room
temperatur
plate
wash
incub
antimonkey
igg
conjug
horseradish
peroxidas
hrp
fitzgerald
industri
dilut
hour
room
temperatur
plate
wash
develop
microliterswel
c
elisa
hrp
substrat
system
thermo
fisher
minut
reaction
stop
ad
mlwell
sodium
dodecyl
sulfat
sigma
absorb
measur
nm
emax
plate
reader
molecular
devic
sunnyval
california
neutral
antibodi
titer
determin
perform
plaqu
reduct
neutral
titrat
prnt
assay
briefli
vero
cell
seed
plate
gener
monolay
day
infect
serum
dilut
prepar
dulbecco
modifi
eagl
medium
incub
approxim
plaqueform
unit
zebovmakona
total
volum
minut
media
remov
cell
serumviru
mixtur
ad
duplic
sampl
incub
minut
mixtur
remov
cell
ml
agaros
eagl
minimum
essenti
medium
fb
overlaid
onto
well
cell
observ
day
incub
plaqu
count
use
neutral
red
stain
neutral
antibodi
titer
serum
sampl
consid
posit
dilut
show
reduct
compar
viru
control
without
serum
nine
healthi
adult
rhesu
macaqu
macaca
mulatta
chines
origin
weight
kg
inocul
intramuscularli
plaqueform
unit
pfu
zebovmakona
either
zebovmakona
n
sebovgulu
n
cs
pool
survivor
zebovc
sebovc
administ
bolu
intraven
infus
approxim
ml
bolu
subcutan
administr
approxim
ml
day
zebovmakona
challeng
control
anim
n
treat
serum
use
administ
total
approxim
ml
split
ml
ml
intraven
subcutan
administr
roughli
equival
approxim
mlkg
twice
much
volum
use
treat
repatri
patient
surviv
treat
anim
receiv
addit
treatment
convalesc
sera
day
zebovmakona
challeng
anim
given
physic
examin
blood
collect
time
challeng
day
zebovmakona
challeng
addit
anim
monitor
daili
score
diseas
progress
intern
filoviru
score
protocol
approv
univers
texa
medic
utmb
institut
anim
care
use
committe
score
chang
measur
baselin
includ
postureact
level
attitudebehavior
food
water
intak
weight
respir
diseas
manifest
visibl
rash
hemorrhag
ecchymosi
flush
skin
score
condit
increas
sever
increas
score
indic
anim
met
criteria
euthanasia
research
conduct
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
adher
principl
state
eighth
edit
guid
care
use
laboratori
anim
nation
research
council
facil
research
conduct
utmb
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
approv
offic
laboratori
anim
welfar
assur
assur
conduct
anim
studi
nhp
biosafeti
level
facil
sever
restrict
number
anim
subject
volum
biolog
sampl
obtain
abil
repeat
assay
independ
thu
limit
statist
analysi
consequ
data
present
mean
calcul
replic
sampl
replic
assay
error
bar
repres
standard
deviat
across
replic
small
number
anim
use
surviv
treat
anim
requir
surviv
signific
attain
rna
isol
whole
blood
mean
viral
rna
minikit
qiagen
place
blood
buffer
avl
primersprob
target
gene
zebov
use
realtim
quantit
polymeras
chain
reaction
qpcr
probe
use
tca
atc
aag
gag
cgc
ctc
carboxytetramethylrhodamin
life
technolog
zebov
rna
detect
use
detect
system
biorad
laboratori
onestep
probe
realtim
qpcr
kit
qiagen
previous
describ
limit
detect
lod
realtim
qpcr
genom
equival
per
gram
tissu
viru
titrat
perform
plaqu
assay
vero
cell
serum
sampl
previous
describ
briefli
increas
dilut
sampl
adsorb
vero
monolay
duplic
well
limit
detect
pfuml
total
white
blood
cell
count
white
blood
cell
differenti
red
blood
cell
count
platelet
count
hematocrit
valu
total
hemoglobin
concentr
mean
cell
volum
mean
corpuscular
volum
mean
corpuscular
hemoglobin
concentr
analyz
use
laserbas
hematolog
analyz
beckman
coulter
blood
collect
tube
contain
ethylenediaminetetraacet
acid
serum
sampl
test
concentr
albumin
amylas
alanin
aminotransferas
aspart
aminotransferas
alkalin
phosphatas
transferas
glucos
cholesterol
total
protein
total
bilirubin
blood
urea
nitrogen
creatin
creactiv
protein
use
piccolo
pointofcar
analyz
biochemistri
panel
plu
analyz
disc
abaxi
necropsi
perform
subject
tissu
sampl
major
organ
collect
histopatholog
immunohistochem
examin
immersionfix
neutral
buffer
formalin
process
histopatholog
analysi
previous
describ
test
whether
earli
convalesc
sera
use
zebovmakona
infect
pool
pcrneg
serum
sever
nhp
surviv
either
zebovmakona
sebovgulu
infect
sebovgulu
convalesc
sera
use
ebov
speci
control
investig
whether
speciesspecif
serum
necessari
treatment
possibl
convalesc
serum
contain
factor
specif
antibodi
necessari
therapeut
benefit
focus
antibodi
aspect
assess
sera
level
igg
follow
zebov
sebov
protein
gp
alon
gp
np
vlp
elisa
high
titer
igg
could
bind
sebov
gp
detect
sebovgulu
sera
compar
minim
level
bound
zebov
gp
vlp
figur
similar
level
igg
could
bind
sebov
zebov
gp
detect
zebovmakona
convalesc
sera
wherea
level
igg
bound
zebov
vlp
high
level
bound
sebov
vlp
minim
figur
crossreact
observ
set
sera
set
higher
level
igg
indic
convalesc
particular
speci
ebov
detect
variat
igg
titer
antigen
individu
donor
except
zebovc
zebov
vlp
next
abil
zebovmakona
sebovgulu
convalesc
sera
neutral
zebovmakona
test
assay
zebovmakona
convalesc
sera
abl
modestli
neutral
zebovmakona
vitro
figur
igg
convalesc
sera
test
qualiti
avid
assay
use
zebov
vlp
appreci
differ
sera
figur
detect
antizebov
igg
observ
neutral
zebovmakona
vitro
zebovmakona
convalesc
sera
assess
regimen
total
convalesc
sera
treatment
everi
day
begin
day
exposur
figur
zebovmakona
nhp
model
infect
six
rhesu
macaqu
infect
intramuscularli
pfu
zebovmakona
figur
either
untreat
n
treat
sebovgulu
convalesc
sera
n
treat
zebovmakona
convalesc
sera
n
anim
observ
clinic
sign
diseas
hematolog
blood
chemic
chang
zebovmakona
exposur
interestingli
sebovgulu
convalesc
anim
surviv
infect
untreat
control
zebovmakona
convalesc
seratr
anim
die
infect
figur
anim
surviv
fever
day
exposur
anorexia
day
mild
depress
day
howev
anim
petechi
rash
moderatetosever
depress
like
anim
untreat
zebovmakona
convalesc
sera
group
determin
whether
treatment
convalesc
sera
led
circul
antizebov
gp
igg
longev
perform
elisa
serum
sampl
obtain
day
exposur
circul
antizebov
gp
igg
detect
day
postexposur
cohort
treat
zebovmakona
convalesc
sera
figur
howev
circul
antizebov
gp
igg
unabl
reduc
infecti
viral
load
figur
viral
rna
load
tissu
figur
anim
treat
zebovmakona
convalesc
sera
wherea
infecti
viral
load
reduc
level
detect
beyond
day
figur
analysi
blood
sampl
reveal
chang
liverassoci
enzym
figur
hematolog
chang
figur
consist
zebov
infect
anim
resolv
chang
also
anim
devoid
typic
gross
patholog
histopatholog
find
label
zebov
antigen
immunohistochem
stain
data
shown
surviv
anim
rais
question
regard
possibl
differ
sebovgulu
zebovmakona
convalesc
sera
consid
data
zmapp
target
zebov
gp
decid
analyz
avid
igg
zebov
gp
instead
combin
np
vlp
done
previous
figur
investig
avid
convalesc
sera
zebov
gp
avid
assay
perform
intriguingli
slight
shift
bind
abil
sebov
convalesc
sera
observ
pool
donor
sera
compar
pool
zebov
convalesc
sera
figur
shift
led
us
analyz
avid
antizebov
gp
antibodi
individu
donor
serum
either
donor
group
avid
sebov
serum
donor
shift
show
similar
trend
compar
zebov
serum
donor
group
compar
combin
donor
data
one
sebov
serum
donor
particular
mark
shift
avid
assay
figur
higher
shift
avid
antizebov
gp
igg
sebov
convalesc
sera
suggest
qualiti
antibodi
might
import
protect
effect
observ
lone
nhp
treat
sera
figur
assess
whether
sebov
convalesc
sera
inde
protect
assess
regimen
sebovgulu
convalesc
sera
treatment
everi
day
begin
day
exposur
zebovmakona
nhp
model
infect
three
nhp
infect
intramuscularli
pfu
zebovmakona
either
untreat
n
treat
sebovgulu
convalesc
sera
previou
studi
n
differ
sebovgulu
convalesc
sera
pool
n
unlik
previou
observ
sebovgulu
convalesc
anim
studi
surviv
infect
die
day
exposur
respect
untreat
control
die
day
exposur
consist
control
initi
studi
figur
anim
petechi
rash
moderatetosever
depress
infecti
viremia
figur
chang
liverassoci
enzym
level
figur
thrombocytopenia
figur
consist
zebovmakona
infect
late
releas
report
support
use
experiment
treatment
evalu
effect
zebovmakona
infect
diseas
convalesc
wholeblood
plasma
infus
treatment
support
use
clinic
trial
support
undoubtedli
stem
report
convalesc
wholeblood
treatment
outbreak
zebovkikwit
infect
treat
patient
surviv
although
author
claim
convalesc
wholeblood
treatment
efficaci
addit
anoth
group
report
likelihood
surviv
treat
patient
similar
surviv
rate
observ
entir
outbreak
treatment
initi
later
time
diseas
onset
correl
surviv
patient
surviv
zebovkikwit
infect
treat
convalesc
whole
blood
patient
essenti
past
stage
associ
morbid
outcom
treatment
occur
therapeut
benefit
convalesc
whole
blood
could
determin
observ
howev
led
renew
interest
control
studi
involv
passiv
immunotherapi
nhp
model
zebov
infect
particular
one
studi
use
convalesc
whole
blood
treat
nhp
observ
benefici
effect
convalesc
whole
blood
use
studi
obtain
nhp
rechalleng
zebov
sever
year
initi
exposur
therefor
blood
may
similar
characterist
convalesc
whole
blood
collect
time
closer
initi
exposur
current
studi
examin
protect
effect
convalesc
sera
obtain
month
initi
zebov
exposur
consist
condit
recent
west
african
zebov
epidem
addit
compar
efficaci
homolog
sera
heterolog
sebov
sera
surprisingli
initi
studi
result
surviv
heterolog
sebov
speci
convalesc
anim
nhp
treat
speciesspecif
sera
die
zebovmakona
infect
sebovgulu
convalesc
sera
crossreact
zebov
gp
titer
sebov
gp
sera
markedli
higher
howev
crossreact
success
antizebov
gp
igg
treatment
follow
develop
zmapp
analyz
whether
sera
use
herein
differ
qualiti
igg
antibodi
zebov
gp
use
avid
assay
interestingli
found
sebovgulu
convalesc
sera
betterqu
antizebov
gp
igg
one
donor
particular
zebovmakona
convalesc
sera
specul
perhap
differ
antizebov
gp
avid
account
surviv
benefit
observ
subsequ
follow
studi
anoth
studi
analyz
sebovgulu
convalesc
sera
well
differ
pool
sebovgulu
convalesc
sera
howev
followup
studi
nhp
treat
heterolog
sebovgulu
sera
surviv
zebovmakona
infect
data
suggest
survivor
initi
studi
figur
may
receiv
protect
benefit
sebovgulu
convalesc
sera
although
small
benefit
sebovgulu
sera
rule
studi
either
importantli
previou
studi
kikwit
variant
zebov
rhesu
monkey
show
rare
case
untreat
control
anim
surviv
challeng
number
untreat
control
anim
newli
develop
zebovmakona
rhesu
monkey
model
high
enough
time
determin
whether
small
percentag
untreat
control
anim
surviv
show
treatment
convalesc
sera
begin
day
zebovmakona
exposur
could
provid
protect
benefit
note
anim
virem
either
infecti
viru
viral
rna
detect
day
treatment
repres
high
bar
therapeut
protect
candid
therapi
delay
treatment
schedul
chosen
part
due
success
zmapp
initi
treatment
day
zebovkikwit
exposur
goal
current
studi
test
whether
virem
nhp
could
show
revers
zebov
infect
treat
convalesc
sera
conclud
convalesc
sera
treatment
initi
nhp
onset
viremia
effect
therapeut
particularli
compar
recent
success
small
interf
rna
zmapp
therapeut
advanc
stage
diseas
howev
possibl
treatment
convalesc
sera
time
earlier
exposur
andor
use
differ
treatment
regimen
may
provid
protect
benefit
addit
use
sera
studi
wherea
convalesc
whole
blood
plasma
obtain
closer
ebov
exposur
use
clinic
trial
may
also
protect
blood
coagul
factor
found
serum
conclud
antizebov
gp
igg
avid
differ
convalesc
sera
account
lone
survivor
observ
question
whether
igg
titer
avid
combin
suffici
passiv
immunotherapi
provid
protect
intrigu
one
